Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptorum Group Limited stock logo
APM
Aptorum Group
$0.91
-6.3%
$0.98
$0.46
$7.49
$5.19M-0.14619,770 shs37,769 shs
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$0.04
$0.04
$0.04
$2.46
N/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
$8.54
$8.54
$0.75
$8.55
$801.09M-0.172.72 million shsN/A
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
$1.53
+4.8%
$1.33
$0.95
$5.99
$16.52M1.4479,758 shs52,512 shs
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$0.00
$0.07
$4.08
$3.50M2.57848,888 shs9.65 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00%-1.87%+7.82%+15.65%-77.83%
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00%0.00%0.00%0.00%0.00%
Chimerix, Inc. stock logo
CMRX
Chimerix
0.00%0.00%0.00%+0.35%+874.89%
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
0.00%+0.69%-5.82%+18.70%-73.11%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,910.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptorum Group Limited stock logo
APM
Aptorum Group
0.811 of 5 stars
0.03.00.00.02.11.70.6
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
0.6703 of 5 stars
1.00.00.04.10.61.70.6
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
4.2266 of 5 stars
3.83.00.03.92.70.80.6
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptorum Group Limited stock logo
APM
Aptorum Group
0.00
N/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
0.00
N/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
2.00
Hold$8.53-0.08% Downside
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
3.50
Strong Buy$13.17760.57% Upside
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CMRX, PHAS, MRKR, APM, and ARAV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2025
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$12.50 ➝ $12.50
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptorum Group Limited stock logo
APM
Aptorum Group
$430K11.32N/AN/A$2.20 per share0.41
ARAVIVE, INC stock logo
ARAV
ARAVIVE
$9.14M0.32N/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
$212K3,778.71N/AN/A$2.17 per share3.94
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
$6.59M2.63N/AN/A$1.73 per share0.88
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
$818K0.00N/AN/A($1.93) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptorum Group Limited stock logo
APM
Aptorum Group
-$4.27MN/A0.00N/AN/AN/AN/A7/30/2025 (Estimated)
ARAVIVE, INC stock logo
ARAV
ARAVIVE
-$76.32MN/A0.00N/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
-$131.07M-$2.13N/AN/AN/A-12,572.13%N/A-174.38%N/A

Latest CMRX, PHAS, MRKR, APM, and ARAV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/31/2025Q4 2024
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
-$0.28-$0.42-$0.14-$0.42$5.25 million$1.22 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptorum Group Limited stock logo
APM
Aptorum Group
N/AN/AN/AN/AN/A
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
N/AN/AN/AN/AN/A
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptorum Group Limited stock logo
APM
Aptorum Group
N/A
0.22
0.22
ARAVIVE, INC stock logo
ARAV
ARAVIVE
N/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
6.33
6.33
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
N/A
6.79
6.79
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
N/A
0.47
0.47

Institutional Ownership

CompanyInstitutional Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
3.80%
ARAVIVE, INC stock logo
ARAV
ARAVIVE
35.80%
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
22.39%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
49.02%

Insider Ownership

CompanyInsider Ownership
Aptorum Group Limited stock logo
APM
Aptorum Group
63.99%
ARAVIVE, INC stock logo
ARAV
ARAVIVE
60.40%
Chimerix, Inc. stock logo
CMRX
Chimerix
13.10%
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
14.50%
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
9.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptorum Group Limited stock logo
APM
Aptorum Group
305.35 million1.93 millionNot Optionable
ARAVIVE, INC stock logo
ARAV
ARAVIVE
2073.56 million29.13 millionNo Data
Chimerix, Inc. stock logo
CMRX
Chimerix
9093.80 million78.15 millionOptionable
MARKER THERAPEUTICS, INC. stock logo
MRKR
MARKER THERAPEUTICS
6011.31 million9.67 millionNot Optionable
PhaseBio Pharmaceuticals, Inc. stock logo
PHAS
PhaseBio Pharmaceuticals
6049.86 million44.92 millionNot Optionable

Recent News About These Companies

MedPharm appoints Bill Humphries as new CEO
Medpharm Appoints Chief Executive Officer
PhaseBio Pharmaceuticals Inc.
PhaseBio Pharmaceuticals, Inc. (PHASQ)
Modified Release Neurology Therapeutics Report 202…
Leading innovators in GLP-1 analogues for the pharmaceutical industry
Alcami Announces CEO Transition
8-K: PhaseBio Pharmaceuticals Inc
BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptorum Group stock logo

Aptorum Group NASDAQ:APM

$0.91 -0.06 (-6.33%)
As of 03:48 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

ARAVIVE stock logo

ARAVIVE NASDAQ:ARAV

$0.04 0.00 (0.00%)
As of 06/27/2025

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Chimerix stock logo

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)
As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

MARKER THERAPEUTICS stock logo

MARKER THERAPEUTICS NASDAQ:MRKR

$1.53 +0.07 (+4.79%)
As of 04:00 PM Eastern

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

PhaseBio Pharmaceuticals stock logo

PhaseBio Pharmaceuticals NASDAQ:PHAS

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.